PMID- 12763927
OWN - NLM
STAT- MEDLINE
DCOM- 20031029
LR  - 20210206
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 102
IP  - 7
DP  - 2003 Oct 1
TI  - ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK 
      rearrangements: report of 6 cases.
PG  - 2568-73
AB  - Expression of ALK protein by lymphoid cells and the description of variant 
      anaplastic lymphoma kinase (ALK) translocations have typically been restricted to 
      cases of T-cell and null anaplastic large-cell lymphoma (ALCL). All such cases 
      result from a novel fusion created by the ALK gene on chromosome 2p23 and NPM on 
      5q35 or other variant translocation partners. A rare variant of diffuse large 
      B-cell lymphoma (DLBCL), originally described in 1997, was thought to overexpress 
      full-length ALK in contrast to a chimeric protein characteristic of ALCL. 
      However, full-length ALK protein lacks tyrosine kinase activity and thus the 
      mechanism of oncogenesis has remained elusive. We describe 6 cases of ALK+ DLBCL 
      characterized by a simple or complex t(2;17)(p23;q23) involving the clathrin gene 
      (CLTC) at chromosome band 17q23 and the ALK gene at chromosome band 2p23. All 
      cases were studied using fluorescence in situ hybridization (FISH), complemented 
      in one case with standard cytogenetic analysis, multicolor karyotyping (M-FISH), 
      and reverse transcriptase-polymerase chain reaction. These results clearly 
      demonstrate that most cases of ALK+ DLBCL share the same mechanism of deregulated 
      ALK expression. Moreover, these results demonstrate the presence of CLTC-ALK 
      fusions in these tumors and extend the list of diseases associated with this 
      genetic abnormality to include classical T-cell or null ALCL, ALK+ DLBCL, and 
      inflammatory myofibroblastic tumors.
FAU - Gascoyne, Randy D
AU  - Gascoyne RD
AD  - Department of Oncogeneiss and Signaling in Hematopoietic Cells, Instiut National 
      de la Sante et de la Recherche Medicale U-563, Centre de Physiopatholgie de 
      Toulouse-Purpan, France.
FAU - Lamant, Laurence
AU  - Lamant L
FAU - Martin-Subero, Jose I
AU  - Martin-Subero JI
FAU - Lestou, Valia S
AU  - Lestou VS
FAU - Harris, Nancy Lee
AU  - Harris NL
FAU - Muller-Hermelink, Hans-Konrad
AU  - Muller-Hermelink HK
FAU - Seymour, John F
AU  - Seymour JF
FAU - Campbell, Lynda J
AU  - Campbell LJ
FAU - Horsman, Douglas E
AU  - Horsman DE
FAU - Auvigne, Isabelle
AU  - Auvigne I
FAU - Espinos, Estelle
AU  - Espinos E
FAU - Siebert, Reiner
AU  - Siebert R
FAU - Delsol, Georges
AU  - Delsol G
LA  - eng
GR  - 1-U01-CA84967-01/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20030522
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Clathrin)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (RNA, Messenger)
RN  - 0 (oncoprotein CLTCL-ALK)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Anaplastic Lymphoma Kinase
MH  - Clathrin/*genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Rearrangement/*genetics
MH  - Humans
MH  - Immunophenotyping
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Lymphoma, B-Cell/*genetics/pathology
MH  - Lymphoma, Large B-Cell, Diffuse/*genetics/pathology
MH  - Oncogene Proteins, Fusion/*genetics
MH  - Protein-Tyrosine Kinases/*genetics
MH  - RNA, Messenger/analysis
MH  - Receptor Protein-Tyrosine Kinases
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Translocation, Genetic
MH  - Tumor Cells, Cultured
EDAT- 2003/05/24 05:00
MHDA- 2003/10/30 05:00
CRDT- 2003/05/24 05:00
PHST- 2003/05/24 05:00 [pubmed]
PHST- 2003/10/30 05:00 [medline]
PHST- 2003/05/24 05:00 [entrez]
AID - S0006-4971(20)44089-3 [pii]
AID - 10.1182/blood-2003-03-0786 [doi]
PST - ppublish
SO  - Blood. 2003 Oct 1;102(7):2568-73. doi: 10.1182/blood-2003-03-0786. Epub 2003 May 
      22.